Health
Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'
Key Points
Jun 24th, 2026 Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect' Jamey Millar, Novo Nordisk's Executive Vice President of US Operations, discussed the company's preparations for the upcoming CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments. Millar highlighted uncertainty about whether patient volume will surge immediately or gradually after the program's July 1 rollout, noting ongoing efforts to educate healthcare providers and pharmacists on...
Jun 24th, 2026
Novo Nordisk US EVP on Wegovy’s Franchise ‘Halo Effect'
Jamey Millar, Novo Nordisk's Executive Vice President of US Operations, discussed the company's preparations for the upcoming CMS bridge program, which will impact Medicare beneficiaries' access to obesity treatments. Millar highlighted uncertainty about whether patient volume will surge immediately or gradually after the program's July 1 rollout, noting ongoing efforts to educate healthcare providers and pharmacists on patient eligibility. He speaks with Romaine Bostick & Katie Greifeld on "The Close."
[Image text:] NOVO NORDISK
47.46
-3.43
6.73%
NVO
Year toDate
66.00
50.00
Jan
Feb
Mar
34.00
Apr
May
2026
Jun
Bloomberg
TheClose
NOVOWEGOVYPILLSALES SEEN21%ABOVE CONSENSUS:BI